Security
GALERA THERAPEUTICS INC Common Stock · GRTXD
GRTXDOTCCommon stockHistorical · closed Aug 3, 2026CIK 1563577Updated Oct 6, 2026
GRTXD price & chart
This listing closed Aug 3, 2026. Live provider charts are shown only for current listings.
About the company
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibitor through clinical development for patients with the hardest-to-treat forms of advanced breast cancer. It was historically focused on developing avasopasem, a small molecule dismutase mimetic, in combination with chemoradiotherapy, to reduce the toxicities of the conventional regimens in patients with head and neck cancer.
In the news
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 5,002,000Source | 8,901,000Source | 37,779,000Source | 6,048,000Source | 16,383,000Source | 6,164,000Source | 7,661,000Source | 19,651,000Source | 7,196,000Source | 10,101,000Source | 26,141,000Source | 44,036,000Source |
| Property, Plant and Equipment, NetUSD | — | 0Source | 198,000Source | — | 56,000Source | — | — | 62,000Source | — | 0Source | 71,000Source | 438,000Source |
| GoodwillUSD | — | 0Source | 881,000Source | — | 881,000Source | — | — | 881,000Source | — | 0Source | 881,000Source | 881,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,473,000Source | 8,455,000Source | 24,379,000Source | 5,230,000Source | 10,749,000Source | 5,500,000Source | 6,686,000Source | 13,466,000Source | 6,375,000Source | 8,289,000Source | 18,257,000Source | 4,266,000Source |
| Assets, CurrentUSD | 4,901,000Source | 8,899,000Source | 31,245,000Source | 5,947,000Source | 11,962,000Source | 6,063,000Source | 7,560,000Source | 15,186,000Source | 7,095,000Source | 10,001,000Source | 21,629,000Source | 38,535,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 428,000Source | 444,000Source | 2,831,000Source | 717,000Source | 1,213,000Source | 563,000Source | 874,000Source | 1,720,000Source | 720,000Source | 1,077,000Source | 3,372,000Source | 3,646,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | 0Source | 1,249,000Source | — | 1,136,000Source | — | — | 1,174,000Source | — | 0Source | 1,212,000Source | 43,000Source |
| Other Assets, NoncurrentUSD | 101,000Source | 2,000Source | 1,948,000Source | 101,000Source | 90,000Source | 101,000Source | 101,000Source | 90,000Source | 101,000Source | 100,000Source | 90,000Source | 1,881,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 151,647,000Source | 151,963,000Source | 164,332,000Source | 151,396,000Source | 154,415,000Source | 1,141,000Source | 152,024,000Source | 154,342,000Source | 645,000Source | 153,770,000Source | 157,326,000Source | 153,217,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | 0Source | — | 0Source | — | — | 0Source | — | — | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 75,000Source | 54,000Source | 54,000Source | 75,000Source | 54,000Source | 75,000Source | 75,000Source | 54,000Source | 75,000Source | 75,000Source | 54,000Source | 28,000Source |
| Retained Earnings (Accumulated Deficit)USD | -460,418,000Source | -451,432,000Source | -431,819,000Source | -459,030,000Source | -445,851,000Source | -308,920,000Source | -457,955,000Source | -441,787,000Source | -307,314,000Source | -456,363,000Source | -437,406,000Source | -378,324,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | 0Source | — | — | — | — | — | — | — | 0Source | -22,000Source |
| Stockholders' Equity Attributable to ParentUSD | -149,222,000Source | -143,062,000Source | -126,553,000Source | -147,945,000Source | -138,032,000Source | 728,000Source | -147,227,000Source | -134,691,000Source | 3,974,000Source | -148,041,000Source | -131,185,000Source | -109,181,000Source |
| Additional Paid in Capital, Common StockUSD | 311,121,000Source | 308,316,000Source | 305,212,000Source | 311,010,000Source | 307,765,000Source | 309,573,000Source | 310,653,000Source | 307,042,000Source | 311,213,000Source | 308,247,000Source | 306,167,000Source | 269,137,000Source |
| Liabilities and EquityUSD | 5,002,000Source | 8,901,000Source | 37,779,000Source | 6,048,000Source | 16,383,000Source | 6,164,000Source | 7,661,000Source | 19,651,000Source | 7,196,000Source | 10,101,000Source | 26,141,000Source | 44,036,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 598,000Source | 914,000Source | 12,630,000Source | 347,000Source | 2,126,000Source | — | 975,000Source | 2,013,000Source | 645,000Source | 1,666,000Source | 4,957,000Source | 13,379,000Source |
| Operating Lease, Liability, CurrentUSD | — | 0Source | — | — | — | — | — | — | — | 0Source | — | — |
| Accounts Payable, CurrentUSD | 434,000Source | 296,000Source | 3,715,000Source | 202,000Source | 812,000Source | 699,000Source | 744,000Source | 1,046,000Source | 265,000Source | 1,275,000Source | 1,375,000Source | 3,581,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 0Source | 1,155,000Source | — | 1,037,000Source | — | — | 1,077,000Source | — | 0Source | 1,117,000Source | 0Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 164,000Source | 618,000Source | 8,784,000Source | 145,000Source | 1,157,000Source | 442,000Source | 231,000Source | 831,000Source | 380,000Source | 391,000Source | 3,449,000Source | 9,754,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 203,000Source | 203,000Source |
| Short-term InvestmentsUSD | — | — | 3,985,000Source | — | — | — | — | — | — | — | 0Source | 27,331,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -1,606,000Source | -1,592,000Source | 149,049,000Source | -18,957,000Source | -59,082,000Source | -62,222,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | 0Source | 0Source | 20,000Source | 259,000Source | 114,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 78,000Source | 137,000Source | 410,000Source | 2,545,000Source | 5,560,000Source | 7,164,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 434,000Source | -531,000Source | -1,010,000Source | -1,416,000Source | -2,206,000Source | -1,463,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | -203,000Source | 0Source | -70,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -875,000Source | -2,238,000Source | -6,049,000Source | -12,145,000Source | -44,848,000Source | -43,426,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | 3,500,000Source | -46,000Source | 27,293,000Source | 23,994,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 0Source | 59,000Source | 25,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 0Source | 635,000Source | 635,000Source | 2,223,000Source | 31,496,000Source | 3,889,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -875,000Source | -1,603,000Source | -1,914,000Source | -9,968,000Source | 13,941,000Source | -15,543,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 4,473,000Source | 8,455,000Source | 5,230,000Source | 10,749,000Source | 5,500,000Source | 6,686,000Source | 6,375,000Source | 8,289,000Source | 18,257,000Source | 4,316,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 91,000Source | 551,000Source | 90,000Source | 723,000Source | 78,000Source | 137,000Source | 410,000Source | 2,545,000Source | 5,560,000Source | 7,164,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 0Source | -2,000Source | 0Source | -4,000Source | — | — | 0Source | -6,000Source | -3,000Source | -1,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | 151,000,000Source | — | — | — |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 3,500,000Source | — | — | — |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | — | — | — | — | 3,500,000Source | — | 3,500,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | 0Source | -48,000Source | 72,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | 151,000,000Source | — | 151,049,000Source | — | — | — |
| Gain (Loss) on Disposition of Assets for Financial Service OperationsUSD | — | — | — | — | — | — | — | — | 3,500,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 1,306,000Source | 3,439,000Source | 1,051,000Source | 2,779,000Source | 1,640,000Source | 1,870,000Source | 5,693,000Source | 11,002,000Source | 22,836,000Source | 20,214,000Source |
| GoodwillUSD | — | — | — | 0Source | — | 881,000Source | — | — | — | 0Source | 881,000Source | 881,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 881,000Source | — | — | — | — | 0Source | 881,000Source | 0Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | 0Source | 2,258,000Source | — | — | — | — | 0Source | 2,258,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | -203,000Source | — | — | — | — | 0Source | -203,000Source | 0Source | 70,000Source |
| Investment Income, InterestUSD | — | — | 48,000Source | 126,000Source | 60,000Source | 149,000Source | 49,000Source | 77,000Source | 248,000Source | 554,000Source | 1,595,000Source | 506,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,388,000Source | -5,581,000Source | -1,075,000Source | -4,064,000Source | -1,606,000Source | -1,592,000Source | 149,049,000Source | -18,957,000Source | -59,082,000Source | -62,222,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -628,000Source | -5,581,000Source | -486,000Source | -4,064,000Source | -726,000Source | -720,000Source | 63,524,000Source | -18,733,000Source | — | — |
| Operating Lease, ExpenseUSD | — | — | 3,000Source | 451,000Source | 4,000Source | 54,000Source | 4,000Source | 3,000Source | 14,000Source | 559,000Source | 191,000Source | 259,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | 0Source | 50,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 0Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 0Source | 188,000Source | 81,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | — | — | 443,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -1,436,000Source | -5,908,000Source | -1,135,000Source | -4,209,000Source | -1,655,000Source | -1,963,000Source | -2,542,000Source | -20,160,000Source | -49,260,000Source | -51,226,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -1,388,000Source | -5,784,000Source | — | — | — | — | 149,049,000Source | -19,160,000Source | -59,082,000Source | -62,292,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | -203,000Source | — | — | — | — | 0Source | -203,000Source | 0Source | 70,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,388,000Source | -5,581,000Source | -1,075,000Source | -4,064,000Source | -1,606,000Source | -1,592,000Source | 149,049,000Source | -18,957,000Source | -59,082,000Source | -62,222,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.01Source | -0.1Source | 0Source | -0.07Source | -0.01Source | -0.01Source | 0.64Source | -0.34Source | — | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.01Source | -0.1Source | 0Source | -0.07Source | -0.01Source | -0.01Source | 0.64Source | -0.34Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 98,503,430Source | 54,392,170Source | 98,503,430Source | 54,392,170Source | 98,503,430Source | 98,503,430Source | 98,503,430Source | 54,633,215Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 98,503,430Source | 54,392,170Source | 98,503,430Source | 54,392,170Source | 98,503,430Source | 98,503,430Source | 98,503,430Source | 54,633,215Source | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 0Source | -2,000Source | 0Source | -4,000Source | — | — | 0Source | -6,000Source | -3,000Source | -1,000Source |
| General and Administrative ExpenseUSD | — | — | 1,306,000Source | 3,439,000Source | 1,051,000Source | 2,779,000Source | 1,640,000Source | 1,870,000Source | 5,693,000Source | 11,002,000Source | 22,836,000Source | 20,214,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 881,000Source | — | — | — | — | 0Source | 881,000Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 149,049,000Source | -25,306,000Source | -59,067,000Source | -62,281,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | — | — | — | — | — | — | — | -1.33Source | -2.3Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | — | — | — | — | — | — | — | -1.33Source | -2.3Source |
| Interest ExpenseUSD | — | — | 0Source | 0Source | — | 0Source | 0Source | 0Source | 0Source | 0Source | 11,414,000Source | 11,571,000Source |
| Investment Income, InterestUSD | — | — | 48,000Source | 126,000Source | 60,000Source | 149,000Source | 49,000Source | 77,000Source | 248,000Source | 554,000Source | 1,595,000Source | 506,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -628,000Source | -5,581,000Source | -486,000Source | -4,064,000Source | -726,000Source | -720,000Source | 63,524,000Source | -18,733,000Source | — | — |
| Operating Lease, ExpenseUSD | — | — | 3,000Source | 451,000Source | 4,000Source | 54,000Source | 4,000Source | 3,000Source | 14,000Source | 559,000Source | 191,000Source | 259,000Source |
| Research and Development ExpenseUSD | — | — | 130,000Source | 305,000Source | 84,000Source | 1,430,000Source | 15,000Source | 93,000Source | 349,000Source | 3,151,000Source | 24,115,000Source | 31,012,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | — | — | 443,000Source | — |
Offerings
Registration 333-251061
Filing attachments
d124753dex991.htm · 8-K · 2026-04-14
EX-99.1 13 d124753dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement Combined company to operate as Obsidian Therapeutics, Inc. and to advance Obsidian’s pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian’s lead product candidate, OBX-115, is a genetically engineered, autologous TIL cell therapy currently in a Phase 2 cl…
Read attachment ↗d124753dex992.htm · 8-K · 2026-04-14
EX-99.2 9 d124753dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Obsidian Therapeutics CORPORATE DECK APRIL 2026 © 2026 Obsidian Therapeutics Information Not Intended for Medical Communication Forward-Looking Statements This presentation includes forward looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, strategy and plans, industry environment, potentia…
Read attachment ↗grtx-ex4_2.htm · 10-K · 2026-03-19
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of securities of Galera Therapeutics, Inc. (the “Company,” “Galera,” “we,” “our,” or “us”) provides a summary of the rights of our capital stock as well as certain provisions of our Restated Certificate of Incorporation (our “Certificate of Incorporation”), and our Amended and Restated Bylaws (our “Bylaws”), each as currently in…
Read attachment ↗